Anti-C1q antibodies are highly prevalent among patients with IgG4-RD, particularly those with renal and skin manifestations.

Innovative Bispecific Antibody Therapies in Cancer Treatment Emerge as Patent Filings SurgeDublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape Analysis" report ...

In 1978, parvovirus—then common to cats—started infecting dogs in Europe. The virus spread quickly around the globe, killing ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, /PRNewswire/ -- Harbour BioMed (the 'Company'; HKEX: 02142), a global ...

Alloy Therapeutics enters multi-year collaboration with Pfizer to develop new antibody discovery platform: Boston, Massachusetts Thursday, February 13, 2025, 13:00 Hrs [IST] Alloy ...

Boston: Alloy Therapeutics Inc., a biotechnology ecosystem company has announced its latest strategic collaboration with ...

Alloy Therapeutics Inc., a biotechnology ecosystem company, has joined forces with Pfizer Inc., to develop a new platform ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.

The year 2015 marked the inception of Sanyou Bio's technological journey, laying the foundation for its core technology platform. The R&D team devoted itself to the development of display vectors, ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology ...